NMDAR
Peripherally acting NMDAR antagonists as new anti-diabetic medication. Novel approach for the reduction of blood sugar levels without risk of hypoglycaemia.
Novel approach for reduction of blood sugar levels without risk of Hypoglycaemia
Preclinical evidence of protection of insulin-secreting beta cells
Possible prevention or delay of diabetes Progression
Good results with starting substance in two clinical studies on human type 2 diabetics (Phase IIa)
Possible enhanced safety and reduced adverse effects compared to the OTC drug dextromethorphan
Antidiabetic Medication
DXO-derivatives that do not efficiently pass the blood brain barrier (BBB), and thus should cause fewer adverse effects on the CNS, but maintain their antidiabetic properties. Therefore, the derivatives might maintain the good safety profile and antidiabetic properties of its starting substance dextrorphan, but with fewer adverse effects.
Licensing
02/12/2016 00:00:00
EP20160805448 20161202
- international:
A61K31/485; A61P25/00; A61P3/00; A61P35/00; C07D221/28; C07D401/04
- cooperative:
A61P3/10; C07D221/28; C07D401/04
Patent application
4501
德國
